Biosynex 過去の業績

過去基準チェック /06

Biosynexの収益は年間平均-2.7%の割合で減少していますが、 Medical Equipment業界の収益は年間増加しています。収益は年間14.5% 21.6%割合で増加しています。

主要情報

-2.7%

収益成長率

-2.8%

EPS成長率

Medical Equipment 業界の成長	21.6%
収益成長率	21.6%
株主資本利益率	-29.9%
ネット・マージン	-39.7%
前回の決算情報	31 Dec 2023

Recent updates

Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet

Oct 30

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Aug 16

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

Jun 29

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Mar 12

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

Jan 20

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

May 05

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Dec 01

収支内訳

Biosynex の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ENXTPA:ALBIO 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費
31 Dec 23	93	-37	36
30 Sep 23	95	-36	32
30 Jun 23	97	-34	28
31 Mar 23	147	-9	25
31 Dec 22	197	16	21
30 Sep 22	248	40	20
30 Jun 22	300	64	19
31 Mar 22	341	84	18
31 Dec 21	383	104	17
30 Sep 21	359	100	17
30 Jun 21	335	96	16
31 Mar 21	244	64	15
31 Dec 20	154	31	15
30 Sep 20	108	19	13
30 Jun 20	61	7	11
31 Mar 20	48	4	10
31 Dec 19	35	1	8
30 Sep 19	34	1	8
30 Jun 19	33	1	8
31 Mar 19	32	1	8
31 Dec 18	31	1	7
30 Sep 18	31	0	7
30 Jun 18	31	0	7
31 Mar 18	31	0	7
31 Dec 17	31	0	7
30 Sep 17	34	1	7
30 Jun 17	38	1	7
31 Mar 17	32	0	6
31 Dec 16	27	0	5
30 Sep 16	20	-1	4
30 Jun 16	12	-1	3
31 Mar 16	11	-1	3
31 Dec 15	10	0	3
30 Sep 15	8	0	2
30 Jun 15	6	0	2
31 Mar 15	5	-1	1
31 Dec 14	4	-2	1
30 Sep 14	4	-2	1
30 Jun 14	3	-2	1
31 Mar 14	2	-2	1
31 Dec 13	2	-2	1

質の高い収益: ALBIOは現在利益が出ていません。

利益率の向上: ALBIOは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ALBIOは利益が出ておらず、過去 5 年間で損失は年間2.7%の割合で増加しています。

成長の加速: ALBIOの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ALBIOは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 12.7% ) と比較することは困難です。

株主資本利益率

高いROE: ALBIOは現在利益が出ていないため、自己資本利益率 ( -29.86% ) はマイナスです。

Biosynex 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

Full year 2022 earnings released

First half 2022 earnings released

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

Full year 2021 earnings released

Recent updates

Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

Investor sentiment deteriorates as stock falls 22%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

Investor sentiment deteriorated over the past week

New 90-day high: €20.60

Investor sentiment improved over the past week

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: €19.90

First half earnings released

New 90-day high: €13.50

New 90-day high: €12.50

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06